The EUpALS Newsletter Spring 2026 edition is out.
Read this and previous issues at als.eu/news/
Don't miss future ones by signing up via als.eu
English
EUpALS
234 posts
EUpALS
@EUpALS
European organization for professionals and people with ALS
Leuven (Belgium) Katılım Kasım 2016
121 Takip Edilen293 Takipçiler
EUpALS brings to your attention the questionnaire for people with ALS and their carers, developed by the ERN-NMD.
The survey in multiple European languages can be found at ec.europa.eu/eusurvey/runne…
Please distribute to your pALS and cALS.
English
EUpALS Industry Partner @NeurosenseT announces publication of results from PARADIGM Phase 2b clinical trial of PrimeC in ALS in JAMA Neurology.
The article presents integrated analysis of PrimeC’s safety profile, clinical outcomes, and biomarker findings over 18 months in pALS.
English
February 11-13, EUpALS attended the TRICALS Masterclass 2026.
Researchers, industry, patient (advocates) and regulators joined forces to improve and accelerate development of ALS treatments.
Watch the aftermovie at
tricals.org/news/tricals-m…
#EUpALS #TRICALS #TogetherWeAreStrong
English
Today is Global Rare Disease Day!
Despite #ALS/#MND is classified as a rare/orphan disease, no less than 50.000 European people live with ALS.
Support the @rarediseaseday campaign by sharing this message.
#RareDiseaseDay #EUpALS #TogetherWeAreStrong
English
BREAKING
EUpALS Industry Partner @argenxglobal shares an update on the adimanebart Phase 2a reALISe study in people living with #ALS/#MND.
Please, read the attached community statement.
#EUpALS #TogetherWeAreStrong
English
EUpALS is partner in EU Horizon project @Hereditary_EU .
Last week we attended the Plenary Meeting 2026 in Lisbon (Portugal).
The infrastructure for federated multimodal data sharing is into place, ready to analyze the data for the #ALS/#MND use case.
#TogetherWeAreStrong
English
EUpALS Industry Partner Vectory Therapeutics announces first participant dosed in PIONEER-ALS Phase1/2 trial of VTx-002, a First-in-Class vectorized antibody targeting TDP-43 pathology in #ALS. The company expects continuing enrolling participants across multiple clinical sites
English
EUpALS is partner in EU project @Real4Reg, in which ALS is a use case.
Join our online Experts Workshop on 27 January 2026 (11:30-13 CET) entitled “Real4Reg Use Case 1 – Lessons Learned on Exploring Real-World Data” by registering for free at forms.gle/9xyurC2pKZ4FBf…
English
EUpALS Industry Partner @biogen published long term results from the QALSODY Phase 3 VALOR study and its open-label extension in SOD1-#ALS.
Read the attached press release, and full paper at jamanetwork.com/journals/jaman…
English
The EUpALS Newsletter Winter 2025 edition is out. Read this and previous issues at als.eu/node/157
Don't miss future ones by signing up via als.eu/subscribe
English
EUpALS is partner in EU project @Hereditary_EU. By liking this forwarded video post, EU residents can win a special #XMAS giveaway of our exclusive project materials.
Pimp up your upcomming winter break and give us a like!
#EUpALS #Togetherwearestrong
HEREDITARY@Hereditary_EU
🧬 HEREDITARY #XMAS Giveaway! ✨ To thank you all for your support throughout the year, the HEREDITARY project is celebrating the holiday season with a special giveaway of exclusive project materials! Good luck to all, and happy holidays! ❄️🎁
English
EUpALS Industry Partner Vectory Therapeutics received FDA clearance to proceed with PIONEER-ALS Phase1/2 trial of VTx-002, a First-in-Class vectorized antibody targeting TDP-43 pathology in #ALS.
The open label study will evaluate 2 dose levels of VTx-002 in 12 adults with ALS.
English
Fantastic news!
Upon nomination by @ALSBelgium, EUpALS Scientific Expert Board member Prof. Philip Van Damme @UZLeuven @leuvenbrainins1 #TRICALS received the @ALSMNDAlliance Forbes Norris Award 2025.
A true recognition for his excellent international #ALS/#MND research and care!
English
EUpALS is proud that Alper Kaya of @alsmnhturkiye received @ALSMNDAlliance Humanitarian Award 2025.
This is a true recognition of Alper's relentless commitment to the ALS/MND community, both national, regional and worldwide.
Many congratulations, Alper!
ALS/MND Alliance@ALSMNDAlliance
✨ The International Alliance of ALS/MND Associations proudly honors Dr. Alper Kaya for his extraordinary global impact. As Chairman of the Turkish ALS/MND Association and someone living with ALS/MND, he’s advanced research, driven policy change, and inspired countless people. 💙
English
EUpALS Industry Partner @NeurosenseT received FDA clearance to initiate the pivotal Phase 3 trial PARAGON for PrimeC in #ALS.
PARAGON is expected to conducted in the US and EU and include 300 people with ALS.
#EUpALS #togetherwearestrong
English
EUpALS retweetledi
🚀 Two cities. One week. From genomic data to brain health innovation.
HEREDITARY made its mark at two major EU health events: X #RIES2025 Forum in Galicia, Spain, and the 5th edition of the @BrainDays in Brussels, Belgium.
🔍 Read the full story: hereditary-project.eu/hereditary-pro…
English
EUpALS attends the Brain Innovation Days.
On day 2, EU Horizon project @Hereditary_EU organised a World Café. HEREDITARY partners @EU_Brain, @Observa_Society and EUpALS brougt other experts together to share ideas to advance trustworthy AI-powered data-driven healthcare solutions
English
EUpALS attends the @BrainDays organised by the @EU_Brain.
On day 1, European policy makers reveiled plans and initiatives to further strenghten innovation in brain research!
English